KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clover Health Investments (CLOV) Current Deferred Revenue (2022 - 2024)

Clover Health Investments' Current Deferred Revenue history spans 3 years, with the latest figure at $17000.0 for Q3 2024.

  • For Q3 2024, Current Deferred Revenue fell 99.98% year-over-year to $17000.0; the TTM value through Sep 2024 reached $17000.0, down 99.98%, while the annual FY2023 figure was $3.1 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $17000.0 in Q3 2024 per CLOV's latest filing, up from $13000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $113.5 million in Q2 2023 to a low of $13000.0 in Q2 2024.
  • Average Current Deferred Revenue over 3 years is $60.6 million, with a median of $96.4 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: rose 7.2% in 2023, then plummeted 99.99% in 2024.
  • A 3-year view of Current Deferred Revenue shows it stood at $96.4 million in 2022, then tumbled by 96.78% to $3.1 million in 2023, then plummeted by 99.45% to $17000.0 in 2024.
  • Per Business Quant, the three most recent readings for CLOV's Current Deferred Revenue are $17000.0 (Q3 2024), $13000.0 (Q2 2024), and $3.1 million (Q4 2023).